Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

874

Participants

Timeline

Start Date

May 25, 2020

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions
Coronary Artery Disease
Interventions
DRUG

OAC + Aspirin 100mg od

Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)

DRUG

OAC + placebo of Aspirin 100mg od

Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)

Trial Locations (51)

13015

Marseille-Hôpital Nord, Marseille

13385

Marseille- Hôpital La Timone, Marseille

21000

CHU de Dijon, Dijon

24000

CH Périgueux, Périgueux

24298

CHU de Montpellier, Montpellier

28630

CH Louis Pasteur - Chartres - Le Coudray, Chartres

29609

CHU de Brest, Brest

30000

CHU de Nîmes, Nîmes

31059

CHU de Toulouse, Toulouse

31076

Clinique Pasteur-Toulouse, Toulouse

33604

Hôpital Haut Lévêque -CHU Bordeaux-Pessac, Bordeaux

34000

Clinique du Millénaire - Montpellier, Montpellier

35033

CHU de Rennes, Rennes

37170

CHRU de Tours, Tours

38028

GHM - Grenoble, Grenoble

38043

CHU de Grenoble, Grenoble

45067

CHR d'Orléans, Orléans

49933

CHU d'Angers, Angers

54500

CHU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy

59037

CHRU de Lille, Lille

59113

CH de Seclin, Seclin

60200

CH Compiègne, Compiègne

62000

CH d'Arras, Arras

62300

CH de Lens, Lens

63000

CHU de Clermont-Ferrand, Clermont-Ferrand

64000

CH de Pau, Pau

64100

CH de la Côte Basque - Bayonne, Bayonne

67000

Clinique Rhena - Strasbourg, Strasbourg

67091

CHU de Strasbourg, Strasbourg

69007

CH St Joseph-St Luc Lyon, Lyon

69677

Hôpital Louis Pradel - Bron, Bron

71100

CH Chalon sur Saône, Chalon-sur-Saône

74370

CH d'Annecy-Genevois, Annecy

75010

Paris-Lariboisière, Paris

75013

Paris-Pitié-Salpêtrière, Paris

75015

Paris-HEGP Cardiologie, Paris

Paris-HEGP Médecine vasculaire, Paris

75877

Paris-Bichat, Paris

76000

Clinique St Hilaire - Rouen, Rouen

76031

CHU de Rouen, Rouen

78153

Hôpital André Mignot - CH de Versailles, Versailles

80054

CHRU d'Amiens, Amiens

84902

CH d'Avignon, Avignon

86021

CHU de Poitiers, Poitiers

87042

CHU de Limoges, Limoges

91106

CH Sud Francilien Corbeil-Essonnes, Corbeil-Essonnes

94000

Hôpital Henri Mondor - Créteil, Créteil

95301

Centre Hospitalier René Dubos - Cergy Pontoise, Cergy-Pontoise

97400

Clinique St Clothilde -La Réunion, La Réunion

06606

CH d'Antibes, Antibes

Unknown

CH Martigues, Martigues

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Hospital, Brest

OTHER

NCT04217447 - Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease | Biotech Hunter | Biotech Hunter